Black checkmark with a sparkle and a curved line underneath on a white background.
Company

VOLITIONRX LTD

Ticker
VNRX
Sector
Industry
Report date
November 12, 2026
Valye AI Score

93

Very high visibility
Recent developments
Recent developments summary

Recent developments include financial management actions, clinical validation milestones, and strategic partnerships advancing VolitionRx's diagnostic programs.

Recent developments:
  • VolitionRx Limited announced a $500,000 partial prepayment of a convertible note, indicating active management of debt obligations [N1].
  • The company validated its Nu.Q NETs biomarker in sepsis, marking a clinical validation milestone [N2].
  • VolitionRx held its Q2 2026 earnings call discussing operational and financial results [N3].
  • Capture-Seq technology demonstrated over 95% detection of early-stage cancers, highlighting technological progress [N4].
  • The company advanced its Nu.Q cancer assay program with a reimbursement submission in France, supporting commercialization efforts [N4].
  • VolitionRx signed a co-marketing agreement with Hologic for the Nu.Q Discover service, expanding strategic partnerships [N5].
  • Multiple buy recommendations from D. Boral Capital and HC Wainwright & Co. were reported in late 2025, reflecting analyst interest [N5,N6,N7,N8].
Overview

VolitionRx Ltd develops and commercializes blood-based diagnostic tests primarily for cancer detection and other medical conditions. The company operates through multiple subsidiaries globally and focuses on proprietary technologies such as Nu.Q and Capture-Seq for early disease detection. Its business model involves research and development, clinical validation, regulatory submissions, and strategic partnerships to advance its diagnostic assays. The company has recently engaged in co-marketing agreements and reimbursement submissions to support commercialization efforts. Financially, VolitionRx reported revenues but continues to operate at a net loss, with liquidity ratios indicating limited short-term financial flexibility as of September 2026.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. VolitionRx Ltd is a biotechnology company focused on developing blood-based diagnostic tests for cancer and other diseases. The company reported revenue of approximately $1.61 million and a net loss of approximately $3.8 million for the nine months ended September 30, 2026. As of that date, it held $2.4 million in cash and equivalents with a current ratio of 0.33, indicating liquidity constraints. Recent developments include validation of biomarkers, advancement of cancer assay programs, strategic co-marketing agreements, and partial prepayment of convertible notes. The company is led by an experienced management team and board with backgrounds in diagnostics and biotechnology.

Scenarios for VNRX

Bull case model:

VolitionRx has demonstrated technological capabilities with its Capture-Seq platform showing over 95% detection of early-stage cancers and validation of biomarkers in sepsis, indicating potential clinical utility. Strategic collaborations and reimbursement submissions may facilitate market penetration. The experienced leadership team and board bring expertise in biotechnology and diagnostics, supporting operational execution. Partial prepayment of convertible notes suggests active management of financial obligations. Continued clinical validation and regulatory progress could enhance the company's commercial prospects.

Bear case model:

The company reported a net loss of approximately $3.8 million for the nine months ended September 30, 2026, with liquidity ratios indicating limited short-term financial resources (current ratio 0.33). The low cash ratio (0.24) and current liabilities exceeding current assets highlight potential liquidity risks. The biotechnology diagnostics market is competitive and subject to regulatory and reimbursement challenges. Execution risks include successful commercialization, regulatory approvals, and market adoption of diagnostic assays. Financial constraints may limit operational flexibility and investment in growth initiatives.

Moat:

VolitionRx's moat is based on its proprietary diagnostic technologies, including Nu.Q and Capture-Seq, which have demonstrated high detection rates for early-stage cancers and other biomarkers. The company's focus on non-invasive blood tests addresses significant unmet medical needs in oncology and sepsis diagnostics. Strategic partnerships, such as the co-marketing agreement with Hologic, and ongoing reimbursement submissions in key markets like France, support potential market access and adoption. The company's intellectual property portfolio and clinical validation efforts contribute to barriers for competitors in the specialized diagnostics space.

Risks overview
Risks summary
Liquidity constraints and operational execution risks are the primary concerns for VolitionRx given its current financial position and the competitive diagnostics market.
Risks details:

• Liquidity Risk: As of September 30, 2026, VolitionRx had a current ratio of 0.33 and a cash ratio of 0.24, indicating limited liquidity to cover short-term liabilities which may constrain operations.
• Operational and Commercialization Risk: The company faces risks related to successfully commercializing its diagnostic assays, including regulatory approvals, reimbursement, and market acceptance.
• Competitive and Market Risk: VolitionRx operates in a competitive biotechnology diagnostics market with evolving technologies and regulatory environments that may impact its market position.

FINAL FORECAST FOR VNRX

Final take one line
VolitionRx exhibits very high visibility through detailed SEC filings and recent news highlighting clinical progress and financial management amid liquidity challenges.
Final take 12 to 24 month view

Business trends: Continued clinical validation of diagnostic assays and strategic partnerships support the company's focus on early disease detection.
Execution milestones: Advancement of reimbursement submissions, co-marketing agreements, and debt management actions.
Key risks: Liquidity constraints, operational execution challenges, and competitive pressures in the biotechnology diagnostics market.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

93
LLM visibility overview
LLM Visibility known facts
  • VolitionRx Ltd is a Delaware corporation with its principal executive offices in Henderson, Nevada [S1].
  • The company completed a one-for-twenty reverse stock split effective April 28, 2026, with all share and per share amounts retroactively adjusted [S1].
  • As of April 28, 2026, there were 8,087,955 shares of common stock issued and outstanding [S1].
  • The company operates through wholly owned subsidiaries including Singapore Volition Pte. Limited, Belgian Volition SRL, Volition Diagnostics UK Limited, Volition America, Inc., Volition Global Services SRL, and majority owned Volition Veterinary Diagnostics Development LLC [S1].
  • The board of directors includes experienced executives with backgrounds in biotechnology, diagnostics, and business development, including CEO Cameron Reynolds and non-executive Chairman Timothy Still [S1].
  • Financial snapshot as of September 30, 2026, shows cash and equivalents of $2.4 million, current assets of approximately $3.23 million, and current liabilities of approximately $9.89 million, resulting in a current ratio of 0.33 and a cash ratio of 0.24 [S2].
  • Revenue for the nine months ended September 30, 2026, was approximately $1.61 million, with a net loss of approximately $3.8 million [S2].
  • Diluted earnings per share for the period was -$0.21 [S2].
  • Recent business developments include a $500,000 partial prepayment of a convertible note [N1].
  • The company validated its Nu.Q NETs biomarker in sepsis [N2].
  • Volition's Capture-Seq technology demonstrated over 95% detection of early-stage cancers [N4].
  • The company advanced its Nu.Q cancer assay program with a reimbursement submission in France [N4].
  • Volition signed a co-marketing agreement with Hologic for the Nu.Q Discover service [N5].
  • Multiple buy recommendations from D. Boral Capital and HC Wainwright & Co. were reported in late 2025 [N5,N6,N7,N8].
  • The company held a Q2 2026 earnings call discussing operational and financial results [N3].
Sources
Sources - Context summary

Generated 2026-11-13

Sources - Earning calls
  • N3
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-04-30 | 10-K/A
  • S2 | 2026-11-12 | 10-Q
Sources - News headlines
  • N1 | 2026-10-28 | www.nasdaq.com | VolitionRx Limited Announces $500,000 Partial Prepayment of Convertible Note | https://www.nasdaq.com/articles/volitionrx-limited-announces-500000-partial-prepayment-convertible-note
  • N2 | 2026-08-26 | www.nasdaq.com | Volition Validates Nu.Q NETs Biomarker In Sepsis; Stock Down | https://www.nasdaq.com/articles/volition-validates-nuq-nets-biomarker-sepsis-stock-down
  • N3 | 2026-08-20 | www.nasdaq.com | Volition (VNRX) Q2 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/volition-vnrx-q2-2026-earnings-call-transcript
  • N4 | 2026-03-25 | www.nasdaq.com | Volition's Capture-Seq Shows Over 95% Detection Of Early-Stage Cancers; Stock Up | https://www.nasdaq.com/articles/volitions-capture-seq-shows-over-95-detection-early-stage-cancers-stock
  • N5 | 2025-12-18 | www.nasdaq.com | D. Boral Capital Maintains VolitionRx (VNRX) Buy Recommendation | https://www.nasdaq.com/articles/d-boral-capital-maintains-volitionrx-vnrx-buy-recommendation-3
  • N6 | 2025-12-05 | www.nasdaq.com | D. Boral Capital Maintains VolitionRx (VNRX) Buy Recommendation | https://www.nasdaq.com/articles/d-boral-capital-maintains-volitionrx-vnrx-buy-recommendation-2
  • N7 | 2025-11-27 | www.nasdaq.com | D. Boral Capital Maintains VolitionRx (VNRX) Buy Recommendation | https://www.nasdaq.com/articles/d-boral-capital-maintains-volitionrx-vnrx-buy-recommendation-1
  • N8 | 2025-11-18 | www.nasdaq.com | D. Boral Capital Maintains VolitionRx (VNRX) Buy Recommendation | https://www.nasdaq.com/articles/d-boral-capital-maintains-volitionrx-vnrx-buy-recommendation-0
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine